Indications of Asciminib

Asciminib is indicated for the treatment of adult patients with: 

Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). 

This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 

Ph+ CML in CP with the T315I mutation. 

from FDA,2021.10